Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics Inc
(NQ:
AQST
)
5.650
-0.020 (-0.35%)
Official Closing Price
Updated: 5:08 PM EST, Jan 25, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aquestive Therapeutics Inc
< Previous
1
2
Next >
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
February 06, 2020
From
GlobeNewswire News Releases
Aquestive Therapeutics Receives FDA Response to Citizen’s Petition
January 12, 2020
From
GlobeNewswire News Releases
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance
January 10, 2020
From
GlobeNewswire News Releases
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock
December 12, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
December 10, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting
December 04, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
December 02, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting
November 26, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film
November 25, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS
November 13, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance
November 05, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics to Attend Two Upcoming Investor Conferences
August 26, 2019
From
GlobeNewswire News Releases
IntelGenx Reports Second Quarter 2019 Financial Results
August 08, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
August 06, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study
August 06, 2019
From
GlobeNewswire News Releases
Aquestive Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
July 29, 2019
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic...
From
GlobeNewswire News Releases
Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019
July 18, 2019
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet...
From
PR Newswire
Aquestive Therapeutics Completes $70 Million Debt Refinancing
July 15, 2019
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive"), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm®...
From
PR Newswire
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
June 07, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic...
From
PR Newswire
Aquestive Therapeutics Completes Enrollment in Libervant™ (diazepam buccal film) Crossover Study
June 04, 2019
- Files first section of rolling New Drug Application (NDA) submission with U.S. Food and Drug Administration (FDA)
From
PR Newswire
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
May 13, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic...
From
PR Newswire
Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
May 08, 2019
- U.S. launch of Sympazan® (clobazam) Oral Film progressing to plan
From
PR Newswire
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
May 08, 2019
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc....
From
GlobeNewswire News Releases
Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer
May 07, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced the...
From
PR Newswire
Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019
April 17, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it...
From
PR Newswire
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
April 16, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the...
From
PR Newswire
Market Trends Toward New Normal in Smartsheet, Spok, TPG RE Finance Trust, DSP Group, Adaptimmune Therapeutics, and Aquestive Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
April 09, 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Smartsheet Inc. (NYSE:SMAR),...
From
GlobeNewswire News Releases
Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 25, 2019
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that...
From
PR Newswire
Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
March 14, 2019
- Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film
From
PR Newswire
Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
March 07, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that...
From
PR Newswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.